These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34331561)

  • 1. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.
    Fernandes MR; Rodrigues JCG; Dobbin EAF; Pastana LF; da Costa DF; Barra WF; Modesto AAC; de Assumpção PB; da Costa Silva AL; Dos Santos SEB; Burbano RMR; de Assumpção PP; Dos Santos NPC
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):837-844. PubMed ID: 34331561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of C677T and A1298C
    Ramos-Esquivel A; Chinchilla R; Valle M
    Anticancer Res; 2020 Aug; 40(8):4263-4270. PubMed ID: 32727753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
    Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
    Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
    Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.
    Sala-Icardo L; Lamana A; Ortiz AM; García Lorenzo E; Moreno Fresneda P; García-Vicuña R; González-Álvaro I
    Reumatol Clin; 2017; 13(6):318-325. PubMed ID: 27751863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of
    Zhong L; Fu Q; Zhou S; Chen L; Peng Q
    BMJ Open; 2018 May; 8(5):e020767. PubMed ID: 29804062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
    Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
    Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
    Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
    Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J
    Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population stratification effect on cancer susceptibility in an admixed population from Brazilian Amazon.
    Vieira PC; Burbano RM; Fernandes DC; Montenegro RC; Dos Santos SE; Sortica VA; Assumpção PP; Ribeiro-Dos-Santos ÂK; Carvalho AA; Dos Santos NP
    Anticancer Res; 2015 Apr; 35(4):2009-14. PubMed ID: 25862854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
    J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.
    Romiti A; Roberto M; D'Antonio C; Onesti CE; Barucca V; Milano A; Gentile G; Lionetto L; Medda E; Mazzuca F; Botticelli A; Falcone R; Simmaco M; Marchetti P
    Anticancer Drugs; 2016 Nov; 27(10):1044-9. PubMed ID: 27557140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
    BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
    Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
    Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin.
    Tsukioka S; Sakamoto E; Tsujimoto H; Nakagawa F; Saito H; Uchida J; Kiniwa M; Fukushima M
    Oncol Rep; 2011 May; 25(5):1407-12. PubMed ID: 21380490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.